TransCode reports 71.4% stable disease rate in updated TTX-MC138 Phase 1a data
TransCode Therapeutics reported updated Phase 1a clinical data for TTX-MC138 in patients with advanced solid tumors, using a September 1, 2026 data cutoff. Ten of 14 efficacy-evaluable patients achieved stable disease, and no dose-limiting toxicities were reported, but the sample is small and disease control was lower at Cycle 6 (35.7%) than at Cycle 3 (57.1%). The filing contains no financial results, so the update bears on the drug's clinical prospects rather than on current financials.
Key points
- 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as best overall response at the September 1, 2026 data cutoff.
- Disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
- No dose-limiting toxicities were reported, including at the highest evaluated dose of 4.8 mg/kg, with 98 doses administered.
- Post-hoc analysis found 6 of 15 evaluable patients (40%) with a growth modulation index above 1.3; the company said biomarker findings are hypothesis-generating.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.